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Azaspiracid (AZA) poisoning was unknown until 1995 when shellfish harvested in Ireland caused illness
manifesting by vomiting and diarrhoea. Further in vivo/vitro studies showed neurotoxicity linkedwithAZA
exposure. However, the biological target of the toxin which will help explain such potent neurological
activity is still unknown. A region of Irish coastline was selected and shellfish were sampled and tested for
AZA using mass spectrometry. An outbreak was identified in 2010 and samples collected before and after
the contamination episode were compared for their metabolite profile using high resolution mass
spectrometry. Twenty eight ions were identified at higher concentration in the contaminated samples.
Stringent bioinformatic analysis revealed putative identifications for seven compounds including,
glutarylcarnitine, a glutaric acid metabolite. Glutaric acid, the parent compound linked with human
neurological manifestations was subjected to toxicological investigations but was found to have no specific
effect on the sodium channel (as was the case with AZA). However in combination, glutaric acid (1mM) and
azaspiracid (50nM) inhibited the activity of the sodium channel by over 50%.Glutaric acid was subsequently
detected in all shellfish employed in the study. For the first time a viable mechanism for howAZAmanifests
itself as a toxin is presented.
T he first evidence of a previously unreported toxic threat from eating shellfish appeared in 1995 when a groupof eight Dutch consumers suffered from food poisoning after consuming shellfish harvested around theshores of Ireland1. The symptoms described appeared to match those associated with classic diarrhoeic
shellfish poisoning (DSP). However when the samples were analysed very low amounts of DSP toxins were found
to be present, and the dinoflagellate organisms known to produce DSP toxins were not observed in the region of
Ireland where the shellfish had been harvested. Another confounding piece of information came from a study
whereby a group of mice were injected with shellfish extracts from the contaminated batch. These mice suffered
from spasms in the hind legs, a slowly progressing paralysis and a range of neurotoxin-like symptoms2, never
before observed with DSP contaminated shellfish3. Within a short period of time the structure of a ‘new’marine
biotoxin had been proposed4 and later revised5. This novel, complex polyether compound was named azaspiracid
and its occurrence in Irish waters has been widely reported causing massive economic damage to the shellfish
industry. Since its discovery over 150 papers have been published on azaspiracid dealing with factors such as the
organism responsible for producing the toxin, namely Azadinium6 and Amphidoma7, the widespread geograph-
ical locations where the toxin has been found8–10, methods of analysis11,12 and identification of multiple azaspir-
acid analogues with differing toxicities13,14. However the determination of the mode of action of azaspiracid has
remained elusive to a wide range of toxicologists who have attempted to determine its biological target13,15. One
recent study claimed that the biological target had been identified as the hERG potassium ion channel16. However
the 50% inhibitory concentrations of toxin required to inhibit K1 current were high (0.64–0.84mM) and not
realistic with regards to concentrations found in contaminated shellfish (0.24mg AZA equivalents.g21)17, causing
intoxications at high doses18, and itsmechanism of action is probably linked to apoptotic targets that respondwith
irreversible kinetics19, and at low doses20. Interestingly a study by Furey et al.21, observed that in animals injected
with partially purified toxins from contaminated shellfish the effects were more severe than that induced by the
pure compound. This group hypothesized that the presence of other azaspiracid analogues and/or matrix
components could be responsible for these differences. Additionally severe cytotoxicity effects, not usually
associated with marine toxins, were first observed by Flanagan et al.22, using crude shellfish extracts rather than
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pure toxin. A large project (ASTOX)23 focusing on the possible
mechanisms of azaspiracid toxicity concluded that the presence of
other DSP toxins (okadaic acid and yessotoxins) did not cause syn-
ergistic effects24. In addition they reported that when pigs were
exposed to relatively high amounts of pure azaspiracid they did
not show any symptoms associated with human intoxication.
Based on existing evidence associated with azaspiracid’s toxicity,
the present authors hypothesized that there may be another com-
pound (as yet unidentified) present in contaminated shellfish which
acts in synergy with azaspiracid to cause the combination of toxic
effects noted in those animals and humans exposed to contaminated
shellfish. In attempt to prove this hypothesis correct, a complex and
elaborate set of investigations were organised.
Results
Targeted analysis. A unique set of blue mussels (Mytilus edulis)
(n 5 24), were collected from Poulnaclough Bay, Ballyvaghan Bay
Co. Galway, Ireland between January and October 2010. The LC-
MS/MS analysis of the shellfish samples (Fig. 1), through the Irish
toxin monitoring programme, showed that between January 6th and
August 1st (n5 15) no detectable amounts of azaspiracid toxins were
present. However immediately after this a toxic episode was recorded
whereby all samples betweenAugust 16th andOctober 9th (n5 9) had
measureable amounts of toxin present. The peak contamination
concentration on August 22nd was 0.92 AZA equivalents (mg.g21)
which is approximately six fold greater than the limit set by the EU
which has been established at 0.16 mg.g21 (EU 853/2004). All toxin
negative samples were pooled as were the toxin containing samples
and from here on described as Pool 1 and Pool 2 respectively.
The importance of the presence of glutaric acid in shellfish in this
study will become apparent in later sections. However as there are no
previous reports on the presence of glutaric acid being measured in
shellfish samples, a dedicated LC-MS/MS assay had to be developed.
A small survey comprising of shellfish samples from the study and
samples from commercial sources (n 5 10) was then performed in
order to estimate the glutaric acid presence and determine its con-
centration. Relatively high levels were detected ranging from 29.5 to
81.1 mg.g21 of dry extract corresponding to 2.95 to 8.11 mg.g21 of
mussel (assuming that the average water content of the shellfish
samples was 90%) (Table 1). No correlation between the levels
of glutaric acid found in AZA contaminated (Pool 2) or non-
contaminated (Pool 1) was observed.
Untargeted analysis. From a total of 4321 ions which were assigned
by TransOmics v1.0 Software, 28 proved to be at significantly higher
levels in AZA contaminated samples (Pool 2). These ions of interest
(highlighted by the S-plot, Fig. 2c) at different levels between the two
sample groups were analysed using a two tailed homoscedastic
student t-test (assuming that the two sample groups were of equal
variance) using Microsoft Excel (2010)25. Graphical representations
of the data were produced using Prism v5.0 (Fig. 3). Using mass
accuracy and isotope similarity as a filter, seven putative IDs for
the features higher in AZA contaminated samples were identified
(Table 2). Interestingly, azaspiracid was detected only in Pool 2 as
expected but proved to be less statistically significant than the
selected ‘‘ions of interest’’. The compounds identified in the AZA
contaminated samples were then reviewed with the aim of
identifying a substance or substances known to be harmful to
humans. Of these compounds glutarylcarnitine proved to be the
most interesting by far. This compound is the main metabolite of
glutaric acid and has been reported to have been identified in urine,
plasma and CSF of patients with glutaric aciduria type I26. This
autosomal recessive inborn error is caused by a severe deficiency of
glutaryl-CoA dehydrogenase activity, which leads to the abnormal
metabolism of lysine, hydroxylysine and tryptophan amino acids
resulting in an accumulation of glutaric acid, 3-hydroxyglutaric
acid and glutarylcarnitine26. This disease is characterized by acute
neurological compromise with generalized convulsions, loss of
motor skills and dystonia27,28. On the basis of the significant
(p ,0.001) increase in levels of the metabolite glutarylcarnitine in
AZA contaminated samples, coupled with the well documented link
with neurological disorders such as glutaric aciduria, glutaric acid
was selected for further toxicology studies.
Toxicology studies. The effects of glutaric acid and glutarylcarnitine
on cellular viability and in hNav1.6 currents. Serial dilutions of
glutaric acid ranging from 0.0001 to 100 mM were added to the
culture medium of the neural cell line SH-SY5Y. After 24 hours or
1 hour incubation, a MTT test was performed to measure
mitochondrial function as a marker of cellular viability. When
glutaric acid was added directly to the cellular medium a decrease of
cellular viability was produced, however the decrease in cellular
Figure 1 | Concentration of azaspiracid (AZA equivalents ug.g21) as determined by LC-MS/MS inmussel samples fromPoulnaclough Bay, Co.Galway
analysed from January to October 2010.
www.nature.com/scientificreports
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viability observed was found to be due to the acidification of the
medium due to glutaric acid presence since when buffered to pH 7.4
no cytotoxic effects were observed (data not shown).
A stably transfected hNav 1.6 HEK cell line was used to evaluate
the activity of glutaric acid over sodium currents. Nav 1.6 is the
voltage gated sodium channel most expressed at nodes of Ranvier
but it is also observed in axons and dendrites29 Nav 1.6 channels
produce well-documented persistent and transient sodium currents
that are important for axonal conduction. Electrophysiological
recordings were obtained in an automated electrophysiological plat-
formwhere compound addition is regulated by amicrofluidic system
controlling a fast and precise solution application and exchange30.
Serial dilutions (0.0001–100 mM) of glutaric acid (buffered to
pH 7.4 and non-buffered) were made in extracellular solution and
added to Nav 1.6 transfected cells and the effects of the compound
over the peak amplitude measured. As was the case in cytotoxicity
assays only non buffered glutaric acid produced a marked effect in
INa with a complete blockage of the current indicating again that the
observed response was simply a function of reducing pH and not
glutaric acid specific (data not shown). Since glutarylcarnitine was
also detected, the same assays were performed with this metabolite
although no toxicity effects were previously reported for it31. As with
glutaric acid case, glutarylcarnitine did not show any effect over
sodium currents (data not shown).
The next phase of the study was to determine if the presence of
glutaric acid or glutarylcarnitine canmodify the effect of AZA-1 over
Table 1 | Glutaric acid concentrations measured in extracts of blue mussel (Mytilus edulis) by LC-MS/MS
Sample type Glutaric acid conc (mg.g21)
AZA positive 1 51.49
AZA positive 2 40.78
AZA positive 3 29.50
AZA positive 4 56.21
AZA negative 1 33.15
AZA negative 2 51.27
AZA negative 3 81.10
AZA negative 4 34.99
Commercial 1 62.50
Commercial 2 48.56
Figure 2 | (a) Representative UPLC ESI1 chromatogram of the polar extract of mussel samples. (b) OPLS-DA scores plot representing AZA
non-contaminated controls (blue squares; n 5 92) vs. azaspiracid (AZA) contaminated samples (red circles; n 5 56). Explained variance (R2) was
98.7%, the predictive ability (Q2) was 98.3% andRMSECVwas 7.56%. (c) The s-plot which corresponds to Fig. 1c. Highlighted in red represent features
which are at significantly higher concentrations in AZA samples when compared with controls. Highlighted in blue are features which are at
significantly lower concentrations in AZA samples when compared with controls (non-contaminated mussel specimens).
www.nature.com/scientificreports
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INa. Since glutaric acid produced a dose-dependent modification in
pH, 1mM was selected for the experiment, a dose that did not affect
the pH and that has been previously used in in vitro assays to study its
effects in neurological systems32,33. Cells were incubated for 5 min
with this proven nontoxic concentration (1mM) and nanomolar
concentrations (1–100 nM) of AZA-1 which alone have been shown
not to modify INa when added to the extracellular solution (Fig. 4A).
These experiments showed that when 1mM glutaric acid (pH 7.4)
was present in the extracellular solution a decrease of INa is observed
with concentrations of AZA-1, ranging from 10 to 100 nM. The
presence of 1mM buffered glutaric acid plus AZA-1 inhibited INa
by 51.73% 6 12.72 (p 5 0.03) (Fig. 4A and 4B).This data showed a
glutaric acid specific effect when present in combination with AZA-
1. However, the related compound detected in mussels, glutarylcar-
nitine (1 mM), did not affect the AZA-1 effects over INa. To
clarify the relationship between AZA-1 and glutaric acid further
experiments were performed. Firstly, cells were incubated for
5 min with AZA-1 50 nM prior to addition of glutaric acid
(pH 7.4) in concentrations ranging from 0.001 to 100 mM. These
concentrations had been previously shown not to modify INa, but
surprisingly after AZA-1 incubation a dose dependent effect can be
observedwhere 10 mMglutaric acid (7.4 mM) inhibited INa by 26.82
6 10.6% and 100 mM by 60.97 6 11.68% (p 5 0.019 and 0.001
respectively)(Fig. 5A and 5B). However, when AZA-1 (50 nM) was
added at the same time with each glutaric acid concentration no
effect is observed, indicating that a preliminary activation of some
target may be necessary (data not shown).
Since glutaric acid has showed Na1/K1-ATPase activity34, an
established inhibitor of this pump (ouabain) was used to verify if
the observed effect could be mediated by the effect of glutaric acid
over it. Cells were incubated for 5 min with 1 mM ouabain prior to
the addition of AZA-1. Once again a similar effect was observed,
where the highest concentrations tested produced a clear inhibition
of INa in the presence of ouabain inhibiting the current in a 46.486
9.25% (p 5 0.03) (Fig. 5C and D). Moreover, glutaric acid neuro-
toxicity has also been related to an impairment of gamma-aminobu-
tyric acid (GABA) production and a consequent decrease in its
levels35, thus the effects of this GABA imbalance over AZA-1 effects
were also tested. The GABA antagonist bicuculline (5 mM) was also
added to a cellular solution for 5 min before AZA-1 application. No
significant effect of AZA-1 inhibition of sodium currents was found.
These results strongly suggest that the effect of glutaric acid over the
Na1/K1-ATPase was responsible for the observed effects and that the
combination of both substances is required to cause the observed
effect on sodium channels.
Discussion
The symptoms of azaspiracid poisoning have never been explained
satisfactorily in terms of describing the target for the toxin. The data
presented provide a plausible explanation of why neurological effects
are observed after extracts containing AZA-1 or partially purified
AZA-1, which contain glutaric acid, affect voltage-gated sodium ion
channels. Previously, it has been shown that AZA-1 produces an
irreversible inhibition of the bioelectrical activity in spinal cord neur-
onal networks but it failed to show any effect over sodium or calcium
voltage-gated channels36. However AZA-1 was only tested in con-
centrations up to 10 nM and purified AZA-1 (. 93%) was used to
perform all the assays. In this current study it has been demonstrated
that concentrations ,100 nM of AZA-1 have no effect on sodium
currents, yet a significant effect was observed in the presence of
1 mM glutaric acid. The levels of glutaric acid found in the shellfish
were in the low mg/mL range and that used in the toxicity studies was
a medium mg/mL dose. Further studies to determine the amount of
glutaric acid required to cause the synergistic effect with AZA are
required.
Azaspiracid poisoning is a fairly new phenomenon. The first evid-
ence of the toxin appeared less than 20 years ago, it suddenly
emerged on the West coast of Ireland and has continued to do so
episodically over this period remains a mystery. The toxin has been
found in many other geographic locations but the only confirmed
cases of associated illness from consuming contaminated shellfish
are linked with shellfish harvested from Irish waters. It may be the
coming together of the azaspiracid toxins, glutaric acid and perhaps
as yet other unknown compounds in filter feeding shellfish are
required to cause the toxic consequences in humans. Changes in
oceans currents caused by climate changemay be another attributing
factor that has been responsible for the bringing together of all the
‘ingredients’ needed to form a cocktail of chemicals in shellfish that
can result in severe food poisoning. It is interesting to note that AZA
has now been detected in shellfish harvested in many parts so the
world8–10 but toxicity has only been associated with product har-
vested in west, south west and north westerly Irish waters. It is
Figure 3 | Graphical representation of the metabolites and their relative
abundances in bothAZA and control samplesmeasured in ESI1. (Ions of
interest which are found to be at higher abundances in AZA samples.
Numbered columns relate to the features labelled in Table 2).
www.nature.com/scientificreports
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possible that the toxin has been present in shellfish from this region
for a considerable time period and the ‘change’ has been the intro-
duction of a source of glutaric acid and possibly other toxic dicar-
boxylic acids. It has been shown that the occurrence of glutaric acid is
strongly influenced by marine, biogenic emissions37. Co-incidentally
but perhaps not a recent study published by Grenfell38 presented
data to show greatly enhanced biogenic emissions were recorded
(1996–1997) at a remote coastal site in western Ireland where many
azaspiracid outbreaks have occurred and at a time close to when the
first azaspiracid outbreaks was recorded (1995). The finding of glu-
taric acid in all shellfish samples analysed (n5 10) from this coastal
region strongly supports this report however a larger scale study of
shellfish from a variety of coastal regions is required to build the level
of knowledge on the possible role of biogenic emissions and toxin
accumulation is filter feeders.
The hypothesis tested in this study was further supported by the
potentiatory effect of glutaric acid on the toxic response to low levels
of azaspiracid. Glutaric acid has been very recently reported to have
an apoptotic effect in neurons39, targeting similar cellular structures
to azaspiracids such as mitochondria and cell morphology19. A com-
bined neurotoxicity of azaspiracid with glutaric acid has been
demonstrated for the first time. The fact that both compounds were
found to be present in shellfish harvested from an area associated
with food poisoning episodes that manifested neurological effects
may well provide an explanation for such events.
Methods
LC-MS/MS analysis of shellfish samples. The EU reference laboratory (EU-RL)
liquid chromatography mass spectrometry method (LC-MS/MS) method (http://
www.aesan.msps.es/en/CRLMB/web/home. shtml) was utilised as the reference
method (Regulation EC 15/2011) for the determination of lipophilic toxins including
azaspiracids 1,2,3 as a requirement of the Irish monitoring programme. The total
azaspiracid content was calculated as azaspiracid equivalents to AZA-1. The toxin
content of wholemussel (Mytilus edulis) samples was determined to select a collection
of samples over a time period from one locationwhereby both non-contaminated and
contaminated samples with azaspiracid could be sourced without the presence of
other regulated marine toxins.
All solvents (methanol, acetonitrile, formic acid) were purchased from Sigma-
Aldrich (Dorset, UK) and were LC-MS grade or equivalent. Ultra-pure water
(18.2 MV?cm21) was generated in-house using a Millipore Milli-Q Integral (Merk
Millipore, Billerica, MA, USA) water purification system. Plastic tissue-culture dishes
were purchased from Falcon (Madrid, Spain). Foetal calf serum, Dulbecco´s modified
Eagle medium/F12 nutrient mixture (DMED/F12), Gluatamax, Minimum essential
medium, non-essential amino acids (MEM NEAA) and G418 were purchased from
Gibco (Glasgow, UK). DetachinTM was purchased from Genlantis (USA). Glutaric
Acid and all other chemicals (of reagent grade) were purchased from Sigma-Aldrich
(UK). Azaspiracid-1 standard (99.9% of purity) was from Laboratorio Cifga (Lugo,
Spain).
Preparation of mussel samples. Mussel samples were collected and flash frozen in
liquid nitrogen for storage at 280uC. Frozen samples were lyophilized (Christ 4L,
IMA Life Sciences, US) and milled to a fine powder under liquid nitrogen
(Freezermill, SpexSamplePrep, USA). Dried homogenate (0.05g) was extracted in
1 mL of methanol/water solution (151, v/v), mixed for 30 minutes, centrifuged at
4,000 g for 10 minutes at 4uC and the supernatant collected. The supernatant was
dried and reconstituted in 700 mL of ultra-pure water. Subsequently, the extract was
filtered through a 0.22 mmCostar Spin-X Centrifuge Tube Filter (10,000 g at 4uC for
5 minutes). Filtered extracts were immediately transferred into Waters Maximum
recovery vials for UPLC-QTof-MS analysis. A pooled sample (QC) was prepared
from 30 mL of extract from each vial.
UPLC-QTof-MS analysis. Chromatography was performed on a Waters Acquity
UPLC I-Class system(Milford, MA, USA), equipped with column oven, coupled to a
Waters Xevo G2-S QTof mass spectrometer (Manchester, UK) equipped with an
electrospray ionisation source operating in positive mode with lock-spray interface
for real time accurate mass correction. The source temperature was 120uCwith a cone
gas flow of 50 L/h, a desolvation temperature of 450uC, and a desolvation gas flow of
850 L/h. The capillary voltage was set at 1.0 kV with a cone voltage of 30 V. Source
offset was 60 (arbitrary unit). Mass spectra data were acquired in centroidmode using
MSE function (low energy: 4eV; high energy: ramp from 15 to 30 eV) over the range
m/z 50–1200 with a scan time of 0.1s. A lock-mass solution of Leucine Enkephalin
(1 ng.mL21) in acetonitrile/water containing 0.1% formic acid (151, v/v) was con-
tinuously infused into the MS via the lock-spray at a flow rate of 5 mL.min21.
A 1.5 mL aliquot of extracted shellfish sample was injected onto an Acquity UPLC
HSS T3 column (2.1 3 100 mm, 1.8 mm, Waters, Milford, MA, USA). The column
oven was set at 45uC, and the sample manager temperature was 6uC. The gradient
elution buffers were A (water with 0.1% formic acid) and B (methanol with 0.1%
Table 2 | A list of the ions found to be at significantly higher levels (p,0.05) in AZA samples (Pool 2) when compared to controls (Pool 1) as
measured in ESI1 and as depicted in Fig. 3
RT M/Z Putative ID Azaspiracid (n 5 56) SEM Controls (n 5 92) SEM p-Value
ESI1 1 1.22 216.1237 Propenoylcarnitine 1.70E106 3.01E104 1.08E106 6.25E104 8.92E-12
2 1.22 262.1293 N/A 2.32E107 4.07E105 1.45E107 8.47E105 2.39E-12
3 1.23 280.1395 N/A 7.12E106 1.16E105 4.39E106 2.44E105 5.00E-14
4 1.53 294.1010 N/A 3.15E106 1.19E105 1.24E106 8.20E104 9.11E-28
5 1.72 136.0761 2-Aminoacetophenone 5.12E106 1.94E105 4.08E106 1.32E105 1.03E-05
6 1.86 1122.4299 N/A 1.86E106 5.32E104 7.01E105 7.12E104 3.23E-22
7 2.11 326.1235 N/A 7.46E106 2.29E105 3.00E106 2.11E105 3.28E-28
8 2.15 344.1338 N/A 5.35E106 1.53E105 2.21E106 1.51E105 2.07E-28
9 3.06 276.1448 Glutarylcarnitine 5.20E107 1.43E106 3.27E107 2.20E106 2.34E-09
10 3.08 258.1338 N/A 4.25E106 1.19E105 2.74E106 1.75E105 5.03E-09
11 3.08 294.1551 N/A 2.18E107 5.27E105 1.37E107 8.85E105 3.08E-10
12 3.10 230.1392 Butenylcarnitine 2.74E106 6.87E104 1.74E106 1.13E105 1.19E-09
13 3.24 285.1149 N/A 2.55E106 6.96E104 1.68E106 7.29E104 3.54E-13
14 4.60 120.0814 N/A 2.74E107 1.72E106 2.26E107 5.78E105 2.17E-03
15 4.61 166.0867 Phenylalanine 5.90E106 2.04E105 4.61E106 1.35E105 1.73E-07
16 6.40 310.1288 N/A 1.52E107 7.92E105 7.60E106 5.05E105 2.32E-14
17 6.40 328.1389 N/A 7.52E106 3.67E105 3.86E106 2.51E105 2.03E-14
18 6.43 292.1183 N/A 1.15E106 5.71E104 6.05E105 3.76E104 8.05E-14
19 6.53 285.1457 N/A 3.52E107 9.74E105 3.09E107 7.15E105 4.52E-04
20 7.14 780.3134 N/A 9.61E105 4.39E104 3.65E105 4.13E104 7.77E-17
21 7.93 188.0716 N/A 3.89E107 1.52E106 3.00E107 6.81E105 1.43E-08
22 7.95 118.0655 N/A 2.52E106 1.35E105 1.81E106 4.45E104 2.08E-08
23 7.95 146.0605 1H-Indole-3-carboxaldehyde 6.38E106 3.52E105 4.52E106 1.24E105 2.84E-08
24 7.96 144.0811 N/A 4.40E106 1.61E105 3.48E106 5.81E104 2.67E-09
25 7.96 205.0978 Tryptophan 3.14E106 5.51E104 2.47E106 4.40E104 8.44E-17
26 8.24 377.1918 N/A 2.37E106 3.85E105 7.22E105 8.43E104 7.30E-07
27 8.53 349.1391 N/A 2.32E106 7.45E104 1.04E106 7.23E104 1.36E-22
28 8.53 367.1498 N/A 4.28E106 1.35E105 1.86E106 1.36E105 3.82E-23
AZA 20.07 842.5049 Azaspiracid 2.67E105 3.03E104 8.35E102 1.27E102 1.24E-21
www.nature.com/scientificreports
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formic acid), and the flow rate was set at 0.4 mL.min21. The elution gradient
(A:B, v/v) was as follows: an isocratic period of 2 min at 99.950.1 followed by a
concave gradient from initial conditions to 1599 over 19 min. After a 2 min isocratic
period at 1599, a linear gradient was applied over 0.1 min to return to the initial
composition 99.950.1 which was held for 1.9 min before the next injection.
Prior to all analyses 10 pooled conditioning samples were injected. For quality
control pooled samples were injected at intervals every 10 samples throughout the
entire experiment to determine the chromatographic reproducibility of retention
times and peak intensities25.
UPLC-MS/MS analysis. Glutaric acid measurement was carried out using a Waters
Acquity UPLC I-Class coupled to a Waters Xevo TQMS triple quadripole mass
spectrometer (Manchester, UK) operating in negative electrospray ionisation.
The source temperature was 150uC with a cone gas flow of 50 L/h, a desolvation
temperature of 400uC, and a desolvation gas flow of 700 L/h. The capillary voltage
was set at 2.0 kV with a cone voltage of 20 V. Data acquisition was in multiple
reaction monitoring mode (MRM). The precursor/product ions monitored were
131.00. 68.95 (collision energy 15 eV), 131.00. 86.95 (collision energy 10 eV) and
131.00. 112.95 (collision energy 10 eV). A 5.0 mL aliquot of extracted shellfish
sample was injected onto an Acquity UPLC BEH column (2.1 3 50 mm, 1.7 mm,
Waters, Milford, MA, USA) maintained at 45uC. Mobile phase consisted of water
with 0.1% formic in channel A andmethanol with 0.1% formic acid in B. The flow rate
was set at 0.4 mL.min21. The gradient profile was isocratic (9951) for 1.8 min then
linear to 1599 over 0.1 min. These conditions were maintained for 1.1 min and then
followed by a 2 min re-equilibration period at initial conditions (9951). Data was
processed using TargetLynxTM software (Waters, Milford, US).
Data analysis. The raw data from the spectral analysis of the mussel extracts was
processed using TransOmics v1.0 Software (Waters Corporation, Milford, USA).
TransOmics is a new data analysis software package that enables the accurate pro-
cessing of high resolution LC-MS spectral data whilst also providing annotation of
putative compounds based on accurate mass measurements and fragmentation
information. This software aids in both the validation of LC-MS approaches and
identification of features within the spectral data. Using TransOmics the spectral data
were aligned to a chosen pooled sample, adduct ions were deconvoluted and ions
abundance of features above the threshold level calculated. All detected ions were
selected against the Progenesis Metascope ‘‘Biomolecules’’ database which provided
putative identifications for around 20% of the identified features.
Following analysis in TransOmics, the raw data were filtered to remove any vari-
ables containing .20% zero values (considered technical noise). The data were
exported to Simca v13.0.3 (Umetrics, Umea, Sweden) for multivariate analysis. As a
quality control measure all the spectral data were Center Scaled and analysed using
principal components analysis (PCA). All pooled samples were found to be tightly
clustered within the center of each representative scores plot which indicates good
reproducibility of the data25. Following this, all data were mean centered and Pareto
scaled (scaling factor 1/!sd) and divided into two groups: toxin negative and toxin
positive prior to analysis by Orthogonal Projections to Latent Structures-
Discriminant Analysis via Partial Least Squares (OPLS-DA). This method was
employed as it ensures the inclusion ofmetabolites present in both high and low levels
in the model, while minimizing the effect of noise40. Predictive powers were based on
the Q2 score produced using Simca P. Essentially the data are divided into 7 parts (by
default) and each 1/7th in turn is removed. A model is built on the 6/7th data left in
and the left out data are predicted from the new model. This is repeated with each
1/7th of the data until all the data have been predicted. The predicted data are then
compared with the original data and the Predicted Residual Sum of Squares (PRESS)
is calculated for the whole dataset. Q2 is calculated form the PRESS value which is
divided by the initial sum of squares and subtracted from one. Models with good
predictive powers have low PRESS scores and high Q2 values25,41. Graphical
representations of the data were produced using Prism (Version 5.0).
The ions of interest (highlighted by the S-plot) at different levels between the two
sample groups were analysed using a two tailed homoscedastic student t test
(assuming that the two sample groups were of equal variance) using Microsoft Excel
(2010)25.
Cell culture. Neuroblastoma cell line SH-SY5Y was purchased from ATCC. Cells
were plated in 25 cm2 flasks and maintained in DMEM/F12 media supplemented
with 10% foetal serum, 100 UI.mL21 penicillin and 100 mg.mL21 streptomycin. Cells
were split weekly using 0.05% trypsin/EDTA.
HEK-293 cell line stably transfected with hNav 1.6 was kindly provided by Dr
Andrew Powell (GlaxoSmithKline R&D, Stevenage, UK). Cells were cultured in
DMEM/F12 medium supplemented with Glutamax, MEMNEAA (1% w/v) and 10%
of foetal bovine serum. G418, 0.4 mg.mL21 was added to the medium. Cells were
incubated in a humidified 5% CO2/95% air atmosphere at 37uC until they reached
80% of confluence. Medium was replaced every 2–3 days and split once a week. Cells
with 80% of confluence are incubated at 30uC for 24–48 h before electrophysiological
measurements.
Cytotoxicity assays. Cell viability was assessed by a MTT (3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazoliumbromide) test as previously described42. Cells were grown
in 96 well plates and incubated with ranging concentrations of the tested compound
(from 0.0001–100 mM) in culture medium. Cultures were maintained in the
presence of the compound at 37uC in humidified 5% CO2/95% air atmosphere for 24
or 1 hour after the exposure time, cells were rinsed and incubated for 60 min with a
solution of MTT (500 mg.mL21) dissolved in Locke’s buffer containing (in mM): 154
NaCl, 5.6 KCl, 1.3 CaCl2, 1 MgCl2, 5.6 glucose and 10 HEPES, pH 7.4 adjusted with
Tris. After washing off excess MTT the cells were disaggregated with 5% sodium
dodecyl sulphate and absorbance of the colored formazan salt was measured at
590 nM in a spectrophotometer plate reader. Saponin was used as a cellular death
control and its absorbance values were subtracted from the other data.
Automated patch clamp electrophysiological recordings.All cells were recorded in
whole-cell patch clamp configuration using an IonFlux 16 system (Fluxion,
California, USA) and the corresponding Ionflux 16 software for cell capturate, seal
formation, whole cell obtaining, data acquisition and analysis. Cells maintained at
30uC for 24–48 h were washed twice with Ca21 and Mg21 free phosphate buffered
saline (PBS) and harvested with 5 mL of DetachinTM solution. After cell detachment,
cells were re-suspended in extracellular solution containing (mM): 2 CaCl2, 1 MgCl2,
100 Hepes, 4 KCl, 145 NaCl, 10 TEA-Cl and 10 Glucose. pH 7.4 and 320 mOsm.
Electrophysiological recordings were carried out at room temperature (6 22uC) in a
96-well IonFluxmicrofluidic plate. This system consists of an automated patch clamp
platform based in a microfluidic system where cells in suspension are captured by
Figure 4 | Effect of the co-application of glutaric acid or glutarylcarnitine
over AZA-1 sodium currents modulation. (A) AZA-1 at nanomolar
concentrations did not produce an inhibition of INa in Nav 1.6 transfected
cells. However a decrease of the current was observed when AZA-1 was
added to pretreated cells with 1mM glutaric acid. (B) Histogram showing
the inhibition of INa peak with the highest AZA-1 concentrations tested in
presence of glutaric acid or glutarylcarnitine. (C) Representative current
traces of INa in the presence of 100 nM AZA-1 alone or in combination
with glutaric acid (pH 7.4).
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suction into ensemble recordings arrays formed by 20 individual micro-channels for
cell voltage clamp in parallel, each of which will trap one cell. Once that the recording
assay is full, suction is applied to obtain whole cell configuration by cellular
membrane breakage30.
For Na1 measurements in hNav1.6 channels, sodium currents (INa) were evoked
by the following protocol. Cells were depolarized to 210 mV for 50 ms after a
100 ms step to 2120 mV from 290 mV holding potential (Vh). The intracellular
solution composition for INa recordings was (in mM): 100 CsF, 45 CsCl, 10 Hepes,
5 NaCl, 5 EGTA corrected to pH 7.4 using CsOH. The contaminating effects of
resistance and capacitance currents were compensated electronically by the soft-
ware. Leak resistance is measured by introducing a short 20 mV pulse at the
beginning of each sweep and measuring the current difference30. A sampling fre-
quency of 10 kHz was used.
Statistical analysis. Data analysis was performed with GraphPad Prism 5 software.
All the assays were performed at least three times. Dose-response curves were
analysed using nonlinear regression. Statistical comparison was performed by
Student’s t-test. P values,0.05 were considered as statistically significant. All data are
shown as the means 6 SEM.
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